Critical Care Antiarrhythmic Drugs Market Report 2026

The critical care antiarrhythmic drugs market size has grown strongly in recent years. It will grow from $1.06 billion in 2025 to $1.13 billion in 2026 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to high incidence of acute cardiac arrhythmias, established role of antiarrhythmic drugs in intensive care units, expansion of emergency cardiac care services, availability of proven intravenous drug formulations, growth in hospital-based critical care infrastructure.

The critical care antiarrhythmic drugs market size is expected to see strong growth in the next few years. It will grow to $1.39 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to rising prevalence of cardiovascular diseases, increasing aging population with cardiac risk factors, expansion of intensive care and emergency services, growing focus on early arrhythmia intervention, demand for rapid stabilization therapies in critical care. Major trends in the forecast period include rising use of rapid-acting intravenous antiarrhythmic drugs, growing dependence on evidence-based protocols in critical care settings, increased use of combination therapy for severe arrhythmias, expansion of antiarrhythmic drug use in emergency cardiac care, steady demand for established and generic critical care antiarrhythmics.

The growing prevalence of cardiovascular disease is expected to drive the expansion of the critical care antiarrhythmic drugs market in the coming years. Cardiovascular disease encompasses conditions affecting the heart and blood vessels, often resulting in serious complications such as arrhythmias, heart attacks, and strokes. The incidence of cardiovascular disease is increasing due to factors such as sedentary lifestyles, poor dietary habits, smoking, and rising levels of obesity and hypertension. The critical care antiarrhythmic drugs market plays a key role in cardiac emergency management by restoring normal heart rhythm and preventing cardiac arrest in patients with severe arrhythmias. For example, in 2023, according to the World Heart Federation, a Switzerland-based non-governmental organization, global deaths caused by cardiovascular disease are projected to reach 0.0222 billion by 2030 and 0.0323 billion by 2050, highlighting the rapidly growing global burden of CVD. Consequently, the increasing prevalence of cardiovascular disease is fueling the growth of the critical care antiarrhythmic drugs market.

Leading companies in the critical care antiarrhythmic drugs market are concentrating on the development of ultra-short-acting, highly selective beta-1 blocker therapies to enhance heart rate control while minimizing adverse effects in critically ill patients. Ultra-short-acting, highly selective beta-1 blocker therapies are drugs that rapidly lower heart rate by selectively targeting beta-1 receptors in the heart, with effects that diminish quickly after administration. For instance, in November 2024, AOP Orphan Pharmaceuticals GmbH, an Austria-based pharmaceutical company, obtained U.S. FDA approval for Rapiblyk (landiolol), intended for rapid ventricular rate reduction in adults with supraventricular tachycardia, including atrial fibrillation and atrial flutter, in critical care settings. Rapiblyk is supplied as a lyophilized powder for intravenous injection in a 280 mg vial and, once reconstituted, is administered at doses ranging from 9.3 to 74.6 µg/kg/min. Its ultra-short half-life enables heart rate reductions of 40-90% within approximately 10 minutes, with minimal effects on blood pressure, making it particularly suitable for use in ICUs, emergency departments, perioperative environments, and cardiac surgical settings. Its rapid onset and offset, along with high β₁/β₂ selectivity of about 255:1, differentiate it from traditional beta-blockers and allow effective rate control without prolonged systemic effects.

In August 2025, Aurobindo Pharma Limited, an India-based pharmaceutical manufacturing company, acquired Lannett for $250 million. Through this acquisition, Aurobindo aims to reinforce its presence in the US market and advance its reshoring strategy by expanding domestic manufacturing capacity and securing a reliable supply of essential medicines. Lannett Company Inc. is a US-based pharmaceutical firm specializing in the development of critical care antiarrhythmic drugs.

Major companies operating in the critical care antiarrhythmic drugs market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Sanofi S.A., Bristol Myers Squibb, Novartis AG, Viatris Inc., Teva Pharmaceutical Industries Ltd., Baxter International Inc., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals Plc, Amneal Pharmaceuticals Inc., Lupin Pharmaceutical Limited, Biocon Limited, Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Upsher-Smith Laboratories LLC., Mayne Pharma International Pty Ltd., Zydus Cadila Healthcare Limited, Amomed Pharma GmbH.

North America was the largest region in the critical care antiarrhythmic drugs market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the critical care antiarrhythmic drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the critical care antiarrhythmic drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the critical care antiarrhythmic drugs market by increasing the cost of imported active pharmaceutical ingredients, sterile injectables, and specialized packaging required for intravenous formulations. these effects have been most pronounced in sodium and potassium channel blocker segments, particularly in north america and europe where api sourcing is globally diversified. asia-pacific regions have experienced supply chain delays due to cross-border trade dependencies. however, tariffs have encouraged domestic manufacturing of critical care injectables and strengthened local supply chains, supporting long-term availability of essential antiarrhythmic drugs.

The critical care antiarrhythmic drugs market research report is one of a series of new reports that provides critical care antiarrhythmic drugs market statistics, including critical care antiarrhythmic drugs industry global market size, regional shares, competitors with a critical care antiarrhythmic drugs market share, detailed critical care antiarrhythmic drugs market segments, market trends and opportunities, and any further data you may need to thrive in the critical care antiarrhythmic drugs industry. This critical care antiarrhythmic drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Critical care antiarrhythmic drugs are medications prescribed to manage life-threatening heart rhythm disorders, such as ventricular fibrillation and ventricular tachycardia, in critical care environments. These drugs are delivered intravenously and work quickly to restore a normal heart rhythm and prevent cardiac arrest. They play a vital role in emergency situations and intensive care units by stabilizing patients with serious cardiac rhythm abnormalities.

The primary categories of critical care antiarrhythmic drugs include beta blockers, calcium channel blockers, sodium channel blockers, potassium channel blockers, and others. Beta blockers are drugs that function by inhibiting the effects of adrenaline, thereby lowering heart rate and blood pressure. The associated diseases include ventricular arrhythmias, supraventricular arrhythmias, and others, and these medications are used across various applications such as hospitals, clinics, ambulatory centers, and others.

The critical care antiarrhythmic drugs market consists of sales of drugs such as amiodarone, lidocaine, and procainamide. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.